🔎 Trials Near Me

Home › Kidney Cancer › Arizona

Kidney Cancer clinical trials in Arizona

8 studies for Kidney Cancer are looking for participants at sites in Arizona.

Cities in Arizona

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  • Research Site, Gilbert
  • Research Site, Goodyear
  • Research Site, Phoenix
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07011719

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • Banner Health, Gilbert
  • Mayo Clinic Hospital, Phoenix
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04981119

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

  • Mayo Clinic Comprehensive Cancer Center, Phoenix
  • University of Arizona, Tucson
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06026410

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • Mayo Clinic Building- Phoenix, Phoenix
  • Mayo Clinic Arizona, Scottsdale
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07227415

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

  • University of Arizona Cancer Center, Tucson
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06234605

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Phoenix
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05433142

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Scottsdale
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

  • Banner MD Anderson Cancer Center, Gilbert
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT06682793

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.